Metabiomics

Executive Summary

Metabiomics is a San Diego-based biotechnology company developing non-invasive microbiome-based diagnostic tests for gastrointestinal diseases, including colorectal cancer and inflammatory bowel disease. Founded in 2010, the company leverages proprietary technology to analyze microbial DNA signatures from stool samples, aiming to provide accurate, non-invasive alternatives to traditional screening methods. With a focus on early detection and health monitoring, Metabiomics targets a growing market driven by increasing awareness of the gut microbiome's role in disease. While the company is private and has limited disclosed funding, its technology aligns with the broader trend toward precision medicine and liquid biopsy. The diagnostic platform has the potential to improve patient compliance and reduce healthcare costs, but faces competition from established players and regulatory hurdles. Metabiomics' ability to secure clinical validation and regulatory approval will be key to its commercial success. The company remains relatively early-stage, with no disclosed revenue or partnerships, but its niche focus on gut health diagnostics positions it for potential growth as the microbiome field matures.

Upcoming Catalysts (preview)

• Q4 2026Clinical trial results for colorectal cancer screening test60% success
• Q2 2027FDA submission or breakthrough device designation50% success
• Q3 2026Strategic partnership with diagnostic or pharmaceutical company40% success